Join

Compare · CARM vs NVO

CARM vs NVO

Side-by-side comparison of Carisma Therapeutics Inc. (CARM) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CARM and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO carries a market cap of $183.15B.
  • Over the past year, CARM is down 32.6% and NVO is down 45.7% - CARM leads by 13.0 points.
  • NVO has hit the wire 8 times in the past 4 weeks while CARM has been quiet.
  • NVO has more recent analyst coverage (25 ratings vs 8 for CARM).
PerformanceCARM-32.62%NVO-48.32%
2025-06-09+0.00%2026-06-05
MetricCARMNVO
Company
Carisma Therapeutics Inc.
Novo Nordisk A/S
Price
$0.15-46.08%
$41.01-4.51%
Market cap
-
$183.15B
1M return
+0.00%
-10.44%
1Y return
-32.62%
-45.66%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
2014
News (4w)
0
8
Recent ratings
8
25
NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.